Shanghai Bio-heart Biological Technology Co., Ltd. (2185.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$1.01 (-3.81%) as of
Key statistics
- Market cap
- 245.85M
- Forward P/E
- -6.70
- EPS (TTM)
- -0.320
- Dividend yield
- 0.00%
- 52-week range
- 0.985 – 8.900
- Beta
- 0.14
- Revenue (TTM)
- 38.45M
- Profit margin
- -196.37%
- Volume
- 148.10k
About Shanghai Bio-heart Biological Technology Co., Ltd.
Shanghai Bio-heart Biological Technology Co., Ltd., together with its subsidiaries, engages in the research, development, and commercialization of invasive treatment products in China. The company develops Bioheart, a bioresorbable scaffolds system, which is in registration stage for percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis, a renal denervation system, which is in clinical stage for the treatment of uncontrolled hypertension and resistant hypertension; and DCB, a sirolimus drug coated balloon catheter, which is in clinical stage for the treatment of instent restenosis. It is also involved in local administration and manufacturing services. The company was founded in 2014 and is headquartered in Shanghai, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Shanghai, China
- Employees
- 63
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.